Clinical Trials Using XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410

Clinical trials are research studies that involve people. The clinical trials on this list are studying XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Citarinostat and PVX-410 with or without Lenalidomide in Treating Patients with Smoldering Multiple Myeloma

    This phase Ib trial studies the side effects of HDAC inhibitor ACY-241 (citarinostat) and XBP1-US / XBP1-SP / CD138 / CS1 multipeptide vaccine PVX-410 (PVX-410) with or without lenalidomide in treating patients with smoldering multiple myeloma. Citarinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Vaccine therapy, such as PVX-410, may help the body build an effective immune response to kill cancer cells. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving citarinostat and PVX-410 with or without lenalidomide may work better in treating patients with smoldering multiple myeloma.
    Location: 5 locations

  • PVX-410 and Pembrolizumab in Treating Patients with HLA-A2 Positive Metastatic Triple Negative Breast Cancer

    This phase Ib trial studies how well XBP1-unspliced (XBP1-US) / XBP1-spliced (XBP1-SP) / CD138 / CS1 multipeptide vaccine PVX-410 (PVX-410) and pembrolizumab work in treating patients with human leukocyte antigen (HLA)-A2 positive triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. PVX-410 may help patients' immune systems stimulate immunity against their tumor cells. Giving PVX-410 and pembrolizumab together may work better in treating patients with triple negative breast cancer.
    Location: 3 locations

  • Depleted Immune Suppressor Stem Cell Transplant in Enhancing Immune Response to Vaccines in Patients with Multiple Myeloma

    This pilot, randomized phase II trial studies how well depleted immune suppressor stem cell transplant works compared to standard stem cell transplant in enhancing immune response to vaccines in patients with multiple myeloma (MM). Chemotherapy and the patient's own stem cells are effective in treating MM, however there is a risk of disease returning due to poor recovery of the immune system as shown to poor response to vaccines to prevent infections. Before chemotherapy, patients' stem cells are collected and certain immune cells called suppressor cells are removed from the stem cells. Patients then receive chemotherapy to kill cancer cells and after that the immune depleted stem cells are returned to them to replace the blood-forming cells that were destroyed by chemotherapy. Giving depleted immune suppressor stem cells transplant to patients with MM may result in a more robust immune response to vaccines after transplant and may prevent MM from returning. It is not yet known whether depleted immune suppressor stem cell transplant is more effective than standard stem cell transplant in enhancing immune response to vaccines in patients with multiple myeloma.
    Location: University of Nebraska Medical Center, Omaha, Nebraska